FY23 revenue view is is based on sacral neuromodulation and Bulkamid revenue each growing 25% compared to FY22. Sees FY23 sacral neuromodulation revenue $277.5M and Bulkamid revenue $64.5M.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AXNX: